ClearPoint Neuro (NASDAQ:CLPT) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

ClearPoint Neuro (NASDAQ:CLPT) announced its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04), Zacks reports. The business had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. ClearPoint Neuro had a negative net margin of 69.08% and a negative return on equity of 122.17%.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• ClearPoint Neuro reported record Q1 2026 revenue of $12.1 million, up 43% year over year, with 16% organic growth driven by its core device businesses and the newly added IRRAflow line.
• Gross margin improved to 64% from 60% a year ago, helped by lower excess and obsolete inventory reserves and early benefit from the IRRAS integration.
• The company reaffirmed full-year 2026 revenue guidance of $52 million to $56 million and said sequential growth should continue through the rest of the year, though first-half timing may be uneven.
• Management highlighted progress across all four growth pillars, including new CAL facility studies, the first Asia-Pacific commercial drug delivery procedure, and expansion of the 3.x navigation platform into Europe and Canada.
• ClearPoint said it has successfully integrated IRRAflow operations and expects the business to become cash neutral as early as 2027, supported by cost synergies, facility consolidation, and broader commercial adoption.

ClearPoint Neuro Stock Down 3.6%

ClearPoint Neuro stock traded down $0.45 during midday trading on Wednesday, hitting $12.19. 779,626 shares of the stock were exchanged, compared to its average volume of 726,113. ClearPoint Neuro has a 52-week low of $8.27 and a 52-week high of $30.10. The business’s 50-day moving average price is $10.32 and its 200-day moving average price is $13.45. The stock has a market capitalization of $365.58 million, a price-to-earnings ratio of -13.40 and a beta of 1.29. The company has a quick ratio of 5.13, a current ratio of 5.91 and a debt-to-equity ratio of 1.75.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC grew its holdings in ClearPoint Neuro by 156.3% during the first quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock valued at $8,813,000 after purchasing an additional 452,043 shares during the period. FirstWave Capital Management LLC purchased a new position in ClearPoint Neuro during the 4th quarter valued at about $4,971,000. Two Sigma Investments LP grew its stake in ClearPoint Neuro by 1,316.1% during the third quarter. Two Sigma Investments LP now owns 310,526 shares of the company’s stock valued at $6,766,000 after acquiring an additional 288,598 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in ClearPoint Neuro during the 4th quarter worth approximately $2,972,000. Finally, UBS Group AG increased its holdings in ClearPoint Neuro by 132.1% during the 3rd quarter. UBS Group AG now owns 360,705 shares of the company’s stock worth $7,860,000 after acquiring an additional 205,295 shares during the period. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on CLPT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Monday, April 20th. Stifel Nicolaus started coverage on shares of ClearPoint Neuro in a research note on Friday, May 8th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, B. Riley Financial upped their price target on ClearPoint Neuro from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $18.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.